Expert oncologists review recent updates in the treatment of acute myeloid leukemia (AML) that were presented at key conferences in 2022.
EP. 1: Overview of Acute Myeloid Leukemia
Opening their discussion on the management of acute myeloid leukemia (AML), expert oncologists provide an overview on the incidence, diagnosis, and stratification of patients.
EP. 2: Current Classifications of Acute Myeloid Leukemia
Expert perspectives on current classification strategies in acute myeloid leukemia and how these guidelines make use of molecular markers.
EP. 3: Molecular Biomarker Testing in Acute Myeloid Leukemia
In light of novel targeted agents made available to patients with AML, panelists consider the value of timely molecular testing in this setting.
EP. 4: Acute Myeloid Leukemia: Optimizing Risk Stratification
Expert oncologists reflect on risk stratification in acute myeloid leukemia and the process of categorizing patients into ‘fit’ versus ‘unfit’ subsets.
EP. 5: Role of Intensive Chemotherapy in Young, Fit Patients With AML
Centering focus on first-line treatment modalities, panelists highlight the ongoing role of intensive chemotherapy in the management of AML.
EP. 6: Frontline Therapy for Patients With AML and FLT3 Alterations
Expert perspectives on the emergence of FLT3-targeted therapies and their role in the first-line setting of acute myeloid leukemia management.
EP. 7: Frontline Treatment Options for Patients With IDH2-Mutated AML
Shared insight on IDH-mutated acute myeloid leukemia and appropriate first-line treatment options in this setting.
EP. 8: Acute Myeloid Leukemia: Frontline Treatment With CPX-351
Comprehensive discussion on the emergence of CPX-351 as a first-line treatment option for patients with acute myeloid leukemia.
EP. 9: Optimizing Management of TP53-Mutated Acute Myeloid Leukemia
Expert oncologists highlight challenges in the setting of TP53-mutated AML and consider appropriate treatment strategies.
EP. 10: Acute Myeloid Leukemia: VEN + AZA Treatment in Patients Unfit for Intensive Chemotherapy
A brief overview of mainstay treatment options in the first-line setting of AML for patients deemed unfit for intensive chemotherapy.
EP. 11: Frontline Treatment in Patients With IDH-Mutated AML Unfit for Intensive Chemotherapy
In the setting of IDH-mutated AML, panelists consider optimal treatment options in patients unfit for intensive chemotherapy.
EP. 12: Novel Venetoclax-Based Regimens in Patients With AML Unfit for Intensive Chemotherapy
A comprehensive review of novel venetoclax-based combination therapy in patients unfit for intensive chemotherapy who are diagnosed with AML.
EP. 13: Role of Stem Cell Transplant in Acute Myeloid Leukemia
Before closing out their discussion on first-line treatment options for patients with AML, expert oncologists reflect on the role of stem cell transplant in AML.
EP. 14: Treatment Strategies in Patients With Relapsed/Refractory AML
Centering its discussion on relapsed/refractory acute myeloid leukemia, the panel highlights broader treatment strategies in this setting.
EP. 15: A Potential Role for IDH-1 Inhibitor Olutasidenib in Relapsed/Refractory AML?
Expert perspectives on the potential role of IDH1-targeted therapy, olutasidenib, in patients with relapsed/refractory acute myeloid leukemia.
EP. 16: Sequencing Therapies in Patients With Relapsed/Refractory AML
Shared insight on how treatments can be optimally sequenced in patients with relapsed/refractory acute myeloid leukemia.
EP. 17: Emerging Treatment Strategies in Acute Myeloid Leukemia
A comprehensive review of emerging treatment options and how they may fit into the treatment landscape of acute myeloid leukemia.
EP. 18: Future Directions in the Management of Acute Myeloid Leukemia
Closing out their discussion on the management of acute myeloid leukemia, expert panelists share their excitement for the future evolution of the treatment landscape.
IDE397 Shows Early Antitumor Activity, Safety in MTAP-Deletion Urothelial Cancer and NSCLC
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer